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Abstract
We report two male cases (4- and 5-years-old) of intrathecal methotrexate overdose. The two boys with 
acute lymphoblastic leukemia were to receive intrathecal injection of methotrexate. Instead of the 
prescribed 12 mg, they both received a dose of 120 mg. The initial cerebrospinal fluid samples showed 
methotrexate concentration of 2.24x10-2M in case 1 and 1.32x10-2M in case 2. The cases were success-
fully treated with cerebrospinal fluid (CSF) exchange and intravenous folinic acid rescue. The favor-
able outcome in our cases suggests that CSF exchange is safe and that folinic acid rescue may be 
adequate to prevent sequelae in patients subjected to intrathecal MTX overdoses up to 120 mg. We 
propose CSF exchange and intravenous folinic acid as the mainstay of treatment. In addition to the 
staff’s failure to check the drug label carefully, the marked resemblance of the two dose preparations 
of MTX may have been contributory. (Turk J Hematol 2011; 28: 63-7)
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Özet
İntratekal (IT) metotreksat uygulaması, merkezi sinir sistemi lösemisinin önlenmesi ve tedavisinde 
yaygın olarak kullanılmaktadır. Metotreksatın yüksek dozda veya uzun süreli uygulamaları ciddi nör-
otoksisiteye yol açabilir. Burada, hatalı olarak yüksek dozda intratekal metotreksat verilen iki olgu 
sunulmaktadır. Akut lenfoblastik lösemi tanısıyla izlenen 4 ve 5 yaşlarındaki iki erkek olguya, reçete 
edilen 12 mg yerine yanlışlıkla 120 mg dozunda intratekal metotreksat uygulandı. Uygulama sonrası 
başlangıç beyin omurilik sıvısı metotreksat düzeyleri sırasıyla 2.24x10-2M ve 1.32x10-2M idi. Olgular 
beyin omurilik sıvısı değişimi ve intravenöz folinik asit desteği ile başarılı bir şekilde tedavi edildiler. Introduction
Intrathecal (IT) methotrexate (MTX) therapy is 
used widely for the prevention and treatment of 
central nervous system (CNS) leukemia [1,2]. IT 
injection of MTX is becoming more popular, and 
may be the only form of CNS-directed therapy in 
selected patients [2]. Exposure to MTX in high con-
centrations or for sustained periods is clearly neuro-
toxic, and various dosage recommendations have 
been suggested to avoid neurotoxicity [3,4]. Clinical 
studies indicate that adults should receive a maxi-
mal IT dose of 12.5 mg of MTX to avoid acute clini-
cal neurotoxicity. Rescue treatments of IT MTX 
overdose may include cerebrospinal fluid (CSF) 
exchange, ventricular washout, folinic acid rescue, 
and the investigational agent carboxypeptidase G2, 
an enzyme that rapidly hydrolyzes MTX into inactive 
metabolites [5-9]. There are only a few reports of 
patients with IT MTX overdose in the literature, and 
the management has not been uniform. In this 
paper, we report two cases of IT MTX overdose. 
Similar reports from the literature and their man-
agement are reviewed.
Case Reports
Case 1
A four-year-old boy, diagnosed with  pre-B cell 
acute lymphoblastic leukemia (ALL) without CNS 
involvement, started treatment according to the 
TRALL-BFM 2000 protocol for standard-risk ALL. 
The incident occurred when he received the fourth 
course of a 36-hour (h) continuous infusion of high-
dose MTX (HD-MTX, 1 g/m2). One hour later, a dose 
of 120 mg MTX instead of the prescribed 12 mg was 
administered IT. Fifteen minutes later, the patient 
complained of intense pain in his legs. Sixty min-
utes after the IT MTX, the patient developed head-
ache and generalized hypertonia, and then IT MTX 
overdose was suspected. The other physical find-
ings of the patient were normal except for anxiety 
and generalized hypertonia. Systemic MTX infusion 
was stopped immediately and exchange of lumbar 
CSF was started 90 minutes (min) after the IT MTX. 
He was returned to the operating theater and a 
repeat lumbar puncture was performed under gen-
eral anesthesia. Twenty milliliters of dark yellow 
CSF was removed by gravity over a period of 20 min. 
No complication was observed during the proce-
dure. CSF MTX concentrations were measured by 
means of an enzyme-inhibition technique [10]. The 
initial CSF sample had MTX concentration of 2.24 x 
10-2 M. 20 ml saline was administered IT instead of 
CSF 1.5 h after the IT HD-MTX. Twenty milliliters of 
normal saline was then introduced, started approxi-
mately 1.5 h after the IT dose. Subsequently, 210 ml 
of CSF were removed in 5-ml portions and replaced 
by a corresponding volume of pre-warmed normal 
saline. Thus, a total volume of 230 ml was exchanged, 
equivalent to 200 ml/m2, over a period of 2 h and 15 
min [7]. Two hours after the IT MTX, folinic acid was 
started intravenously (IV) at a dose of 100 mg single, 
and then doses of 10 mg every 6 h for 24 h 
[5,13,15,16]. Dexamethasone was also used at a 
dose of 0.15 mg/kg IV every 6 h for 2 days. CSF 
examination, liver and kidney functions and electro-
lytes were found in normal limits. At 1 and 6 months, 
electroencephalogram (EEG) and a brain comput-
ed tomography (CT) scan were normal. The patient 
remained in normal neurological status thereafter. 
No signs of neurotoxicity were observed during the 
following four years.
Case 2
The second patient was a five-year-old boy with 
T cell ALL, without CNS involvement, in whom 
treatment was started according to the TRALL-BFM 
2000 protocol for medium-risk ALL. During the 
maintenance phase (Protocol II 45th day therapy), 
an IT dose of 120 mg of MTX instead of the intended 
12 mg was accidentally given by the pediatrics staff. 
Takiplerinde klinik gidişin iyi olması, 120 mg’a kadar yüksek doz intratekal metotreksat uygulanmış 
hastalarda, beyin omurilik sıvısı değişimi ve folinik asit kurtarma tedavisinin sekelleri önleme açısından 
yeterli olabileceğini göstermektedir. Bu hatalı uygulamaya asistanların ilaç dozlarını kontrol etmedeki 
hatalarının ve farklı dozlardaki metotreksat preparatlarının benzer kutularda üretilmesinin yol açtığı 
düşünülmüştür. (Turk J Hematol 2011; 28: 63-7)
Anahtar kelimeler: Metotreksat, intratekal, yüksek doz, tedavi
Geliş tarihi: 31 Aralık 2009   Kabul tarihi: 22 Haziran 2010
Kazancı et al.
Intrathecal methotrexate overdose and treatment Turk J Hematol 2011; 28: 63-7 64A vial with a 10-fold higher concentration of MTX 
had erroneously been used for the preparation of 
the injection solution. Ninety minutes after the IT, 
the patient developed headache. The mistake was 
discovered 2 h later, and then 200 ml of CSF were 
exchanged with normal saline in 5-ml portions over 
a 3-h period via lumbar puncture. The initial CSF 
sample had a MTX concentration of 1.32 x 10-2M. 
Two hours after the IT MTX, folinic acid was started 
IV at a dose of 100 mg single, and then doses of 10 
mg every 6 h for 24 h. Dexamethasone was also 
used at a dose of 0.15 mg/kg IV every 6 h for 2 days. 
No neurological signs were observed before or after 
the CSF exchange procedure. The child remained 
asymptomatic in complete remission, and EEG and 
CT of the brain performed six months after the inci-
dent were normal. Written informed consent was 
obtained from both of the patients’ family.
Discussion
Methotrexate (MTX) has been used extensively 
in the treatment of various malignancies, including 
lymphoblastic leukemia and lymphoma. HD-MTX 
with leucovorin rescue is used to treat osteosarco-
ma (8-12 g/m2) and ALL (≤8 g/m2). The toxic 
effects of MTX are myelosuppression, mucositis, 
nephrotoxicity, hepatotoxicity, and neurotoxicity 
with acute or chronic encephalopathy [11-17]. 
Acute encephalopathy generally develops within 
5-14 days after IT MTX or HD-MTX and may include 
headache, nausea, emesis, lethargy, altered mental 
status, blurred vision, aphasia, hemiparesis, and 
seizure. Chronic encephalopathy develops slowly, 
may progress, and can permanently impair neuro-
logic function. Transient acute encephalopathy has 
been clinically observed in 3%-15% of cancer 
patients after HD- MTX [12,15,16]. Most patients can 
resume MTX therapy without permanent neurologi-
cal sequelae, although 10% - 56% may experience 
recurrence on rechallenge [12,15,16]. The patho-
physiology of MTX-induced acute encephalopathy 
is largely unknown but does not appear to be relat-
ed to MTX pharmacokinetics [12]. The usual dose 
for IT administration is 12-15 mg. Management of IT 
MTX overdose is not uniform and, in fact, cases 
described in the literature have been treated with 
different approaches [18-24]. The highest reported 
IT dose given to patients who survived was 650 mg 
[5]. The neurotoxicity of MTX is both route- and 
dose-dependent. There is little neurotoxicity when 
MTX is given orally or intravenously, as the drug 
does not reach significant concentration in the CSF. 
However, IV HD MTX has been associated with CNS 
toxicity, and systemic toxicity may be seen follow-
ing IT administration. Common  findings included 
behavioral abnormalities, focal sensorial and motor 
signs and abnormal reflexes [15]. Manifestations of 
IT MTX overdoses are dose-dependent. It is associ-
ated with little or mild toxicity at less than 100 mg. 
However, doses in excess of 100 mg, and particu-
larly in excess of 500 mg, may cause significant 
morbidity and mortality [5,19].
To our knowledge, 13 cases of IT MTX overdose 
have been reported in the literature (Table 1). 
Twelve of the 13 reported incidents involved chil-
dren between the ages of 2-12 years. Eight patients 
suffered from ALL and the other four had non-Hodg-
kin’s lymphoma. Nine cases received 20-125 mg of 
IT MTX. In one of them, folinic acid rescue was 
administered IT and resulted in a fatal event. Nine 
cases were treated with folinic acid, dexametha-
sone and CSF exchange. No neurologic long-term 
sequelae were observed in any of these nine 
patients [20-24]. Three cases received 600-650 mg 
of IT MTX and underwent ventriculolumbar perfu-
sion or CSF exchange, which are considered effec-
tive if performed promptly [5,6,18]. In ventriculo-
lumbar perfusion, CSF is exchanged for warmed, 
isotonic saline solution [6,18]. 
From these reports, it is obvious that severe tox-
icity is expected when an IT MTX overdose of more 
than 600 mg occurs. Carboxypeptidase G1 and G2 
are investigational agents that rapidly hydrolyze 
MTX into inactive metabolites [9]. It has been suc-
cessfully used IT for treatment of IT MTX overdose 
[18]. However, these agents are not commercially 
available at present.
Incorrect prescription and failure to check the 
drug label carefully prior to the injection are appar-
ently the most immediate errors [25]. In our report-
ed cases, the marked resemblance of the two 
strengths of parenteral MTX preparations (i.e. 50 
mg/5 ml and 500 mg/5 ml, respectively) may also 
have been contributory. 
In conclusion, our patients were treated success-
fully with IV high doses of folinic acid and lumbar 
CSF exchange. Cases receiving overdoses of IT MTX 
should first be treated with CSF exchange and IV 
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nurses who treat malignant diseases must be very 
careful in all stages of disease care, such as in the 
prescribing, ordering and administering of medi-
cines and the following of adverse or unexpected 
effects.
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